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Introduction: Guidance is limited for invasive staging in patients 
with lung cancer without mediastinal disease by positron emission 
tomography (PET). We developed and validated a prediction model 
for pathologic N2 disease (pN2), using six previously described risk 
factors: tumor location and size by computed tomography (CT), 
nodal disease by CT, maximum standardized uptake value of the pri-
mary tumor, N1 by PET, and histology.
Methods: A cohort study (2004–2009) was performed in patients 
with T1/T2 by CT and N0/N1 by PET. Logistic regression analysis 
was used to develop a prediction model for pN2 among a random 
development set (n = 625). The model was validated in both the devel-
opment set, which comprised two thirds of the patients and the valida-
tion set (n = 313), which comprised the remaining one third. Model 
performance was assessed in terms of discrimination and calibration.
Results: Among 938 patients, 9.9% had pN2 (9 detected by invasive 
staging and 84 intraoperatively). In the development set, univariate 
analyses demonstrated a significant association between pN2 and 
increasing tumor size (p < 0.001), nodal status by CT (p = 0.007), 
maximum standardized uptake value of the primary tumor (p = 0.027), 
and N1 by PET (p < 0.001); however, only N1 by PET was associated 
with pN2 (p < 0.001) in the multivariate prediction model. The model 
performed reasonably well in the development (c-statistic, 0.70; 95% 
confidence interval, 0.63–0.77; goodness of fit p = 0.61) and validation 
(c-statistic, 0.65; 95% confidence interval, 0.56–0.74; goodness-of-fit 
p = 0.19) sets.
Conclusion: A prediction model for pN2 based on six previously 
described risk factors has reasonable performance characteristics. 
Observations from this study may guide prospective, multicenter 
development and validation of a prediction model for pN2.
Key Words: Prediction model, Pathologic N2 disease, Mediastinoscopy, 
Lung cancer.
(J Thorac Oncol. 2013;8: 1170-1180)
Mediastinal lymph node involvement in patients with lung cancer is an important determinant of appropriate ther-
apy and, therefore, optimal outcomes. Randomized data show 
that the use of positron emission tomography (PET) decreases 
the incidence of futile thoracotomies by up to 50% through 
better detection of mediastinal and distant disease.1–3 Not sur-
prisingly, the community at large has rapidly adopted PET for 
lung cancer staging.4,5 An estimated 30% to 50% of patients 
who undergo PET are found to have a positive mediastinum.6–8 
Although there is little disagreement that a positive mediasti-
num by PET should be evaluated by invasive mediastinal stag-
ing,9,10 it is less clear whether a negative mediastinum by PET 
requires further evaluation.
Pooled data show that 15% to 26% of patients who have 
a negative mediastinum by PET will have pathologic N2 (pN2) 
disease discovered at the time of resection.6,7 Single-institution 
experiences from Asia, the United States, and Europe reveal 
that pN2 disease is detected intraoperatively in 6% to 16% of 
patients who had a negative mediastinum by PET.11–16 The rate 
of pN2 varies according to histologic findings, grade, tumor 
location, size, and maximized standardized uptake values 
(SUV
Max
), evidence of N1 disease by PET, and evidence of 
nodal disease by computed tomography (CT). These findings 
have led some individuals to advocate for selective invasive 
mediastinal staging based on the presence of these risk factors. 
However, there is no standard approach to quantify the prob-
ability of pN2 disease on the basis of multiple risk factors.
We sought to develop and validate a prediction model 
for pN2 disease. This study was based on the institutional 
experience at Memorial Sloan-Kettering Cancer Center, where 
surgeons practice selective pretreatment invasive staging.
PATIENTS AND METHODS
A retrospective cohort study was conducted using 
patients with radiographic early-stage lung cancer, who 
underwent pulmonary resection at Memorial Sloan-Kettering 
Cancer Center between January 2004 and May 2009. The 
patients excluded were: those who did not undergo PET; who 
had evidence of mediastinal disease or metastasis by PET; who 
had evidence of a T3 or T4 lesion by CT; who had suspected 
or confirmed synchronous, metachronous, or recurrent lung 
cancer; who had a questionable diagnosis of lung cancer on 
pathologic review; who had received induction therapy without 
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invasive pretreatment mediastinal staging; who had undergone 
exploratory thoracotomy or thoracoscopy without resection; 
and who had no intraoperative nodal sampling performed or 
had missing information on pretreatment risk factors for pN2 
disease. The institutional review board approved this study 
and waived the need for consent.
For patients with a negative mediastinum by PET, the 
general approach to preoperative mediastinal staging was 
selective invasive staging based on clinical factors suggestive 
of a high risk of occult pN2 and the belief that the patient 
would benefit more from induction rather than adjuvant che-
motherapy. The decision to selectively stage the mediastinum 
was made on a case-by-case basis by the individual surgeon. 
The general approach to intraoperative mediastinal staging 
was sampling or dissection of lymph node stations most likely 
to drain the resected lung, lobe, or segment.
STATA (Special Edition 9.2; Statacorp, College Station, 
TX) was used to conduct all statistical analyses. Fisher’s exact 
test was used to compare categorical variables. A Kruskal–
Wallis rank sum test was used to evaluate differences in non-
normally distributed continuous variables across groups. 
Logistic regression analysis was used to evaluate the signifi-
cance of potential two-way interactions between suspected risk 
factors for pN2 disease. Kaplan–Meier methods were used to 
estimate overall survival, starting from the date of resection. 
Differences in the risk of death were evaluated using Cox 
regression analysis adjusted for clustering among surgeons. 
Deaths were ascertained by linkage to the Social Security 
Death Index, with follow-up through December 31, 2010. 
p values less than 0.05 was considered to indicate significance.
A prediction model calculates the probability of an 
event on the basis of the presence or absence of risk factors for 
that event. Logistic regression was used to predict the prob-
ability of pN2 disease—detected either by pretreatment inva-
sive staging or at the time of operation. Selection of variables 
was guided by risk factors for pN2 disease, which have been 
previously described in the literature.11–16 Only those variables 
known to clinicians before the institution of first therapy were 
considered for inclusion in the model. For instance, several 
studies describe pathologic tumor size to be a risk factor for 
N2 disease.14,15 As pathologic tumor size cannot be known 
before resection, we assumed tumor size determined by CT to 
be a reasonable surrogate. Six variables were included in the 
final model: tumor location, tumor size, extent of nodal dis-
ease by CT, SUV
Max
 of the primary tumor, N1 disease by PET, 
and histologic findings. Tumor location and size were deter-
mined by CT. Central lesions were defined as those located in 
the inner two thirds of the lung on CT.9 In a sensitivity analy-
sis, we used an alternative definition of centrality: the inner 
one third of the lung.10
To evaluate the performance of the prediction model, the 
entire cohort was randomly split into a development set (con-
sisting of two thirds of the patients) and a validation set (con-
sisting of the remaining one third of the patients). Development 
of the model was conducted using data from the development 
set only and was guided by the desire to categorize risk factors 
in a clinically meaningful and simple fashion while avoiding a 
potentially overfitted model. Multiple models were considered, 
varying the number of categories for categorical variables, 
varying the approach to modeling continuous variables (cat-
egorization, splines, nonlinear parameterization guided by 
fractional polynomial regression, and log transformation), 
and including interaction terms. Validation of the model was 
performed using both the development and the validation sets. 
Calibration—how well the predicted probabilities from the 
multivariate model match actual probabilities—was visually 
assessed using calibration plots and was formally tested using 
the Hosmer–Lemeshow goodness-of-fit test. Discrimination 
was assessed using the c-statistic. This metric ranges from 0.5 
(no discriminatory power equivalent to a coin toss) to 1 (per-
fect discrimination between 2 possible outcomes).
An exploratory analysis was conducted to compare 
expected outcomes associated with alternative invasive stag-
ing strategies. For a prediction model to be used in clinical 
practice, a cutoff for the probability of pN2 disease would 
have to be selected as a trigger for invasive mediastinal stag-
ing. We used an empirical approach to select a cutoff, using 
the Youden Index.17 This method examines all possible cutoffs 
in the range of a continuous variable (in this case, the prob-
ability of pN2 disease) and selects the cutoff that provides the 
maximum additional sensitivity for the same specificity as that 
of the uninformative marker. We also evaluated two clinically 
defined cutoffs based on a high-risk and a low-risk tolerance 
for failing to diagnose pN2 disease in the preoperative setting. 
Performance was evaluated by the use of two endpoints: (1) 
the proportion of patients with pN2 disease detected before 
treatment, and (2) the proportion of invasive procedures per-
formed among those who ultimately did not have pN2 disease. 
In scenarios where patients are selected by use of the predic-
tion model to undergo invasive staging and cases of patients 
undergoing routine invasive staging, only some patients will 
have pN2 disease detected preoperatively, as the sensitivity of 
invasive staging is not 100%. To estimate the proportion of 
patients with pN2 disease detected before treatment, we mul-
tiplied the number of patients selected for invasive staging by 
the sensitivity of invasive staging, divided by the total number 
of patients with pN2 disease. The sensitivity of invasive stag-
ing was estimated using data from this cohort.
RESULTS
Table 1 provides a summary of overall patient and 
disease characteristics, disease management, and stage-based 
5-year survival for the entire cohort. Ninety-seven of 938 
patients (10.3%) underwent invasive mediastinal staging, and 
mediastinoscopy was the most frequently used diagnostic 
modality. No nodal tissue was obtained from five patients 
(5.2%)—four of whom underwent mediastinoscopy and one 
who underwent transbronchial node aspiration. Among the 92 
patients from whom nodal tissue was obtained, a median of 
three (range, 1–4) nodal stations were sampled and a median of 
five (range, 1–18) nodes were evaluated. The median number 
of nodal stations and number of nodes evaluated were greater 
for those who underwent mediastinoscopy. The number of 
nodal stations sampled during pretreatment invasive staging 
did not vary significantly across surgeons, but the number of 
nodes sampled did (Appendix Tables A1–A4). Invasive staging 
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identified pN2 disease in nine patients before first therapy, 
eight of whom subsequently received induction therapy. Only 
one patient had multistation disease. Of the 92 patients who 
underwent invasive staging with successful acquisition of 
tissue, a total of 18 were ultimately found to have pN2 disease; 
nine of these cases were identified by invasive staging. Thus, 
the overall sensitivity of pretreatment invasive staging was 
50% (95% confidence interval [CI], 26%–74%).
A total of 93 patients had pN2 disease detected either 
by pretreatment invasive staging or by intraoperative nodal 
staging. Of the nine patients who had pN2 disease identified 
preoperatively, six had persistent N2 disease, and two had N1 
disease detected intraoperatively. Intraoperative mediastinal 
nodal assessment identified an additional 84 cases of previ-
ously undetected pN2 disease. A median of two (range, 1–5) 
mediastinal nodal stations were assessed, with a median of 
four (range, 1–57) nodes evaluated. Multistation disease was 
present in 14 patients, with one patient having three-station 
disease and the remaining two-station disease. The median 
number of nodal stations and number of nodes evaluated var-
ied significantly (all p < 0.001) by approach to resection and 
by surgeon (Appendix Tables A1–A4). As expected, survival 
rates varied significantly by pathologic nodal status (Fig. 1). 
TABLE 1.  Characteristics of the Patient Cohort
Characteristics All (n = 938)
Age (yr)
 Mean ± SD 67.8 ± 10.5
 Median (range) 69 (35–96)
Male sex 42.4
Race
 White 87.2
 Black 4.5
 Asian 2.5
 Other 2.4
 Missing 3.5
Comorbiditya
 Pulmonary 28.0
 Cardiac 57.4
 Renal 12.7
 Endocrine 2.8
Predicted FEV
1
 percentage
 Median (range) 89 (28–169)
 Missing 2.1
Predicted DLCO percentage
 Median (range) 83 (26–163)
 Missing 5.9
ASA score
 1 1.4
 2 42.8
 3 55.2
 4 0.5
 Missing 0.1
Invasive staging
 Mediastinoscopy 9.5
 EBUS 0.9
 TBNA 0.1
Induction therapy 2.8
Approach to resection
 Open 64.7
 VATS 29.4
 Robotic 5.9
Extent of resection
 Wedge 5.7
 Segmentectomy 9.8
 Lobectomy 79.0
 Bilobectomy 2.4
 Pneumonectomy 3.2
Margin status
 R0 98.5
 R1 1.2
 R2 0.3
Final histology
 AC 35.3
 AC with BAC 33.3
 BAC 0.2
 Squamous 17.4
(Continued)
TABLE 1. (Continued)
Characteristics All (n = 938)
 Large-cell 2.4
 NSCLC NOS 0.1
 Carcinoid 6.3
 Small-cell 1.8
 Other 3.3
Pathologic stage
 IA 50.3
 IB 25.6
 IIA 5.1
 IIB 6.9
 IIIA 10.5
 IIIB 1.3
 IV 0.2
 0 0.1
Adjuvant therapy 7.1
5-yr survival by stageb
 IA 85.1 (80.6–88.6)
 IB 73.1 (65.6–79.2)
 IIA 63.7 (42.3–79.0)
 IIB 58.9 (44.5–70.7)
 IIIA 51.0 (38.7–62.0)
 IIIB 57.2 (21.6–82.7)
Data are percentages, unless otherwise noted.
aColumns do not total to 100% because patients may have more than one comorbidity.
bBecause of the small number of patients in these groups, survival could not be 
estimated for those with stage IV (n = 2) and stage 0 (n = 1) disease.
AC, adenocarcinoma; ASA, American Society of Anesthesiologists; BAC, 
bronchioalveolar carcinoma; DLCO, diffusion capacity of the lung for carbon monoxide; 
EBUS, endobronchial ultrasound; FEV
1
, forced expiratory volume in 1 section; NOS, 
not otherwise specified; NSCLC, non–small cell lung cancer; SD, standard deviation; 
TBNA, transbronchial node aspiration; VATS, video-assisted thoracoscopic surgery.
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Table 2 summarizes the final stage, management, and out-
comes of patients with pN2 disease.
Univariate analyses of the relationship between known 
risk factors and pN2 disease were performed using the develop-
ment set (Table 3). With the exception of tumor location (cen-
tral versus peripheral) and histologic findings, all previously 
described risk factors were associated with increased rates 
of pN2 disease. Given these unexpected findings, a post hoc 
univariate analysis was conducted using the entire cohort, to 
evaluate whether reduced power in the small development set 
might have accounted for the lack of a statistically significant 
association. Even among the entire cohort, tumor location (p = 
0.128) and pretreatment histology (p = 0.059) were not associ-
ated with pN2 disease.
A prediction model was developed using the 625 patients 
in the development set (Table 4). The model had a c-statistic of 
0.70 (95% CI, 0.63–0.77). A c-statistic of 0.7 to 0.8 is gener-
ally considered indicative of a model with a good discrimina-
tory ability. The goodness-of-fit test revealed a nonsignificant 
p value (p = 0.56) indicating no significant differences between 
observed and expected values across deciles of risk. A non-
significant goodness-of-fit test is generally considered indica-
tive of a model with a good fit. Other potential models—that 
categorized variables with greater granularity, that modeled 
continuous variables using nonlinear parameterization, or that 
included interaction terms—were evaluated, but resulted in 
unstable estimates or dropped observations. Predicted prob-
abilities ranged from 1.6% to 58.0% in the development set 
and 1.6% to 55.4% in the validation set. The prediction model 
performed reasonably well in the validation set (c-statistic, 
0.65; 95% CI, 0.56–0.74; goodness-of-fit p = 0.19). The lower 
c-statistic in the validation set is generally considered indica-
tive of a model with fair discriminatory ability. Figures 2 and 
3 show receiver operator curves and calibration plots, respec-
tively, for the development and validation sets.
Because only one a priori risk factor was significantly 
associated with pN2 disease in the prediction model (Table 4), 
we conducted several post hoc analyses to further explore this 
surprising discovery. The use of an alternative definition for cen-
trally located tumors did not change the results. Concerns over 
reduced power to detect associations in the development set led 
us to repeat the multivariate regression analysis using the entire 
cohort. In this model, evidence of N1 disease by PET, evidence 
of N1 disease by CT (p = 0.02), and pretreatment identification 
of adenocarcinoma (AC) (p = 0.041) were associated with a 
FIGURE 1.  Long-term survival by lymph node 
status. pN0, pathologicN0; pN1, pathologicN1; 
pN2, pathologicN2.
TABLE 2.  Stage, Management, and Outcomes of Patients 
with Pathologic N2 Disease
Characteristic All (n = 93)
Pathologic stage (%)
 T1N2M0 45.2
 T2N2M0 46.2
 T3N2M0 3.2
 T4N2M0 5.4
Management (%)
 Resection only 18.3
 Induction chemotherapy 4.3
 Induction and adjuvant chemotherapy 4.3
 Induction chemotherapy and  
adjuvant radiation therapy
3.2
 Adjuvant chemotherapy 49.5
 Adjuvant radiation therapy 3.2
 Adjuvant chemoradiation 10.8
 Adjuvant therapy unknown 6.5
5-yr survival stratified by  
managementa (%)
 Resection only 31.4 (7.2–59.9)
 Induction chemotherapy 33.3 (0.9–77.4)
 Induction and adjuvant chemotherapy 75.0 (12.8–96.1)
 Adjuvant chemotherapy 46.9 (27.4–64.2)
 Adjuvant chemoradiation 90.0 (47.3–98.5)
 Adjuvant therapy unknown 16.7 (0.7–52.7)
aBecause of the small numbers of patients in these groups, it was not possible to 
estimate survival for the following groups: induction chemotherapy, resection, and 
adjuvant radiation therapy; adjuvant chemotherapy; and adjuvant radiation.
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higher risk of pN2 disease. We examined a model that included 
only statistically significant risk factors: nodal status by CT, 
nodal status by PET, and pretreatment histology. Compared 
with the model in Table 4, a parsimonious model performed no 
better in terms of discrimination (development set c-statistic, 
0.69; 95% CI, 0.63–0.75; validation set c-statistic, 0.62; 95% 
CI, 0.54–0.76) and was poorly calibrated when the validation 
set was analyzed (goodness-of-fit p < 0.001).
Another factor that may have affected the relationship 
between known risk factors and pN2 disease is the use of pre-
treatment clinical variables rather than pathologic variables. 
Accordingly, we evaluated discordance between pre- and 
postoperative tumor size and histology (Appendix Tables 
A5 and A6). Among patients who did not receive induction 
therapy, 44% (95% CI, 40%–47%) had discordance between 
pre- and postoperative tumor size, as defined by T classifica-
tion. Among those who had a preoperative diagnosis of can-
cer, pre- and postoperative histology were discordant in 48% 
(95% CI, 43%–53%) of subjects. The use of pathologic rather 
than clinical size and final rather than preoperative histology 
improved the performance of the model in both the develop-
ment set (c-statistic, 0.73; 95% CI, 0.68–0.80; goodness-of-fit 
p = 0.54), and the validation set (c-statistic, 0.68; 95% CI, 
0.60–0.76; goodness-of-fit p = 0.68).
An exploratory analysis was conducted to examine 
potential outcomes associated with five alternative inva-
sive staging strategies (Table 5). The routine invasive stag-
ing strategies, and no invasive staging, were compared with 
three other strategies that used the prediction model, with 
differing cutoffs for invasive mediastinal staging. The Youden 
Index was used to empirically derive the cutoff for invasive 
staging,which was a probability of N2 disease greater than or 
equal to 8.3%. For instance, for a patient with a central, 2-cm 
tumor with an SUV
Max
 of 5.2, without evidence of mediastinal 
nodal disease by CT, without evidence of hilar nodal disease 
by PET, and with a pretreatment biopsy showing AC, the pre-
dicted probability of pN2 disease was 10.9%. By the use of 
prediction models with either an empirically or a low-risk tol-
erance clinically derived cutoff, this patient would be selected 
to undergo invasive mediastinal staging. As the empirically 
derived sensitivity of invasive staging is only 50%, not all 
patients selected for invasive staging will have pN2 disease 
detected preoperatively. Table 5 estimates the expected out-
comes for the entire cohort of patients by use of each strategy. 
TABLE 3.  Univariate Analyses of Known Risk Factors for 
Pathologic N2 Disease among Patients in the Development 
Set (n = 625)
Variable
Patients with 
Pathologic N2 
Disease/Total 
Patients (%) p
Location — 0.263
 Peripheral 17/209 (8.1) —
 Central 47/416 (11.3) —
Radiographic size (cm) <0.001
 ≤1.0 8/32 (25.0) —
 1.1–2.0 10/232 (4.3) —
 2.1–3.0 22/185 (11.9) —
 3.0–5.0 19/144 (13.2) —
 5.1–7.0 4/20 (20.0) —
 ≥7.0 1/12 (8.3) —
Nodal status by CT 0.007
 N0 47/539 (8.7) —
 N1 7/34 (20.1) —
 N2/N3 10/52 (19.2) —
SUV
max
 of the primary tumor 0.027
 ≤1.9 6/127 (4.7) —
 2.0–3.4 7/113 (6.2) —
 3.5–5.9 16/128 (12.5) —
 6.0–10.4 17/134 (12.7) —
 ≥10.5 18/123 (14.6) —
Hilar nodal status by PET <0.001
 N0 48/577 (8.3) —
 N1 16/48 (33.3) —
Pretreatment histology 0.148
 No informationa 26/257 (10.1) —
 AC 26/188 (13.8) —
 AC with BAC 1/43 (2.3) —
 Squamous 4/54 (7.4) —
 Large/NSCLC NOS 5/37 (13.5) —
 Other 2/46 (4.4) —
aNo information refers either to patients who did not undergo pretreatment lung 
biopsy, or those who did and had a benign or a nondiagnostic result.
AC, adenocarcinoma; BAC, bronchioalveolar carcinoma; CT, computed tomography; 
NSCLC NOS, non–small-cell lung cancer not otherwise specified; PET, positron emission 
tomography; SUV
max
, maximum standardized uptake value.
TABLE 4.  Prediction Model of Pathologic N2 Disease 
Developed among the Development Set (n = 625)
Variable Coefficient SE p
Location
 Peripheral Referent
 Central  0.268 0.313 0.392
Radiographic size  0.052 0.094 0.582
Nodal status by CT
 N0 Referent
 N1  0.034 0.547 0.951
 N2/3  0.658 0.422 0.120
SUV
max
 of the primary tumor  0.008 0.029 0.789
Nodal status by PET
 N0 Referent
 N1  1.571 0.410 <0.001
Pretreatment histology
 No information/all other Referent
 AC  0.328 0.291 0.260
 AC with BAC −1.362 1.040 0.190
 Squamous −0.652 0.579 0.260
 Constant −2.846 0.354 <0.001
AC, adenocarcinoma; BAC, bronchioalveolar carcinoma; CT, computed tomography; 
PET, positron emission tomography; SE, standard error; SUV
max
, maximum standardized 
uptake value.
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The use of different cutoffs to trigger invasive staging modi-
fies the tradeoff between better pretreatment detection of pN2 
disease and avoidance of invasive procedures for patients who 
do not ultimately have pN2 disease.
Finally, subgroup analyses were conducted using patients 
with pathologically proven AC to explore whether histologic 
grade or molecular information might be used to enhance the 
predictive ability of future models. Rates of pN2 disease varied 
significantly across tumor grade, with notably, no cases of pN2 
disease among those with well-differentiated AC (well differen-
tiated, 0.0%; moderately differentiated, 13.0%; poorly differenti-
ated or undifferentiated, 16.0%; and grade not reported, 13.5%; n = 
643; p < 0.001). Rates of pN2 disease were not associated with 
a mutation in either KRAS (KRAS mutation, 14.6%; wild-type, 
11.3%; n = 265; p = 0.56) or epidermal growth factor receptor 
(EGFR mutation, 14.1%; wild-type, 10.8%; n = 364; p = 0.57).
DISCUSSION
We developed and validated a prediction model for 
pN2 disease using six previously described risk factors for 
pN2.11–16 The model had reasonable performance characteris-
tics. Several unexpected findings and post hoc and exploratory 
analyses from this study may guide prospective, multi-institu-
tional development and validation of a prediction model for 
pN2 disease.
Surprisingly, of six previously described risk factors for 
pN2 disease, only one (N1 disease by PET) was associated 
with pN2 disease in our development cohort. Post hoc analyses 
from our study suggested two possible contributing factors: 
(1) reduced power to detect associations in the smaller devel-
opment set, and (2) the use of clinical variables as surrogates 
for pathologic variables—for instance, radiographic versus 
pathologic size or pretreatment biopsy versus final pathologic 
histology. Although the use of pathologic variables improved 
the performance of our prediction model, these variables can-
not and should not be used for model development because 
this information is obviously not available to the provider 
before resection. Our post hoc analyses also lend support to 
the notion that selection of variables during model develop-
ment should be guided by a priori risk factors, rather than by 
FIGURE 2. A, ROC (development set). B, ROC for 
the (validation set). ROC, receiver operator curve.
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statistically significant relationships. Limiting our model to 
only variables with a statistically significant association with 
pN2 disease undermined the performance of the model.
Another possible reason why we did not observe a rela-
tionship between pN2 disease and previously described risk 
factors is the lack of a true relationship. Previous studies, like 
ours, have been single-institution investigations that may not 
be generalizable. Furthermore, variable inclusion and exclu-
sion criteria, definitions for and the number of risk factors, 
and differential management of confounding factors make 
it difficult to interpret results across studies. For instance, 
among seven investigations,11,13–16,18,19 four studies described 
a significantly higher risk of pN2 disease among patients with 
central tumors, whereas three others observed no relationship. 
There are at least two different definitions for tumor central-
ity,9,10 and not all previous investigations handled confounding 
factors. Despite testing both definitions and using multivariate 
regression analysis, we found no relationship between central 
tumors and increased risk of pN2 disease. Given the different 
findings and methods across studies, there is legitimate uncer-
tainty about a true relationship between central tumors and the 
risk of pN2 disease. Similarly, there may be uncertainty about 
the relationship between pN2 disease and other risk factors. 
This uncertainty argues for a prospective, multi-institutional 
evaluation of risk factors for pN2 disease, which uses a set of 
potential risk factors, on which there is a general consensus.
There are three other prediction models for pN2, two 
of which were published after the start of our study. The first 
was developed using a secondary data analysis of patients who 
had potentially resectable lung cancer and had enrolled in the 
Canadian Lung Oncology Group randomized trial of selective 
versus routine mediastinoscopy.20 The original trial enrolled 
patients between 1987 and 1990, and thus the applicability 
of the prediction model is limited in the current era, in which 
FIGURE 3. A, Calibration plot (development 
set). The dashed line indicates perfect concor-
dance between observed and predicted prob-
abilities of pN2. The vertical bars represent 95% 
CIs for the actual rate of pN2. B, Calibration plot 
(validation set). The dashed line indicates perfect 
concordance between observed and predicted 
probabilities of pN2. The vertical bars represent 
95% CIs for the actual rate of pN2. CI, confi-
dence interval; pN2, pathologic N2.
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PET is usually used to stage lung cancer.4,5 Two recent predic-
tion models evaluated patients from Asia with clinical stage 
IA lung cancer.19,21 Each study identified four unique predic-
tors, and their models had reasonable performance character-
istics. Our study differed in that we (1) evaluated all patients 
with radiographically diagnosed early-stage lung cancer with 
a negative mediastinum by PET, (2) used a priori–selected 
rather than statistically defined risk factors for pN2 disease, 
and (3) explored empirically and clinically derived probability 
cutoffs that would trigger invasive staging. These differences 
aside, the multinational efforts to develop prediction models 
for pN2 disease suggest there is international interest in using 
clinical decision-making tools to aid lung cancer staging.
One perceived limitation of this investigation is that the 
sensitivity of mediastinoscopy was substantially lower in our 
study (50%) than in reports from pooled analyses (78%).10 It is 
important to note that the prevalence of pN2 in pooled analy-
ses was 39%, whereas, in our study it was 10%. Although it is 
a well-established epidemiologic principle that disease preva-
lence does not affect the sensitivity of a diagnostic test, it is usu-
ally observed that diagnostic tests perform variably in different 
patient populations. The underlying prevalence of pN2 is likely 
a good surrogate for different patient populations. Prior pooled 
analyses included patients with discretely enlarged mediastinal 
nodes, a normal mediastinum with either a central tumor, or 
strong suspicion of N1 disease or peripheral stage I tumors, 
and also some patients with extensive mediastinal infiltration.10 
In contrast, our cohort included only patients with a negative 
mediastinum by PET. Most would agree that these two patient 
populations are not comparable, and thus, it is reasonable to 
expect mediastinoscopy to perform differently across studies.
Another perceived limitation of this study is the low 
overall rate of mediastinoscopy. Rates of mediastinoscopy in 
this investigation (~10%) are far lower than those reported in 
population-based databases (~20%).8 However, it is not possi-
ble to compare rates, because the patient populations are again 
different (i.e., operated patients with a negative mediastinum 
by PET versus all newly diagnosed patients with non–small-
cell lung cancer). Moreover, the low mediastinoscopy rate 
reflects the institutional bias toward a philosophy of selective 
(rather than routine) invasive mediastinal staging.
Our exploratory analysis comparing various staging 
strategies provides an objective basis by which to assess the 
potential effectiveness of prediction models in cancer staging. 
Changing the probability cutoff for invasive staging modifies 
the tradeoff between better pretreatment detection of pN2 dis-
ease and avoidance of invasive procedures for patients who do 
not ultimately have pN2 disease. What is less obvious is the 
finding that a strategy of routine invasive staging does not lead 
to detection of all cases of pN2—instead, it is limited by the 
sensitivity of the diagnostic test in a given patient population. 
Routine invasive staging has associated risks, although small 
ones.22,23 If surgeons and institutions adhere to practice guide-
lines,9,10 most patients will undergo invasive mediastinal stag-
ing. Use of a prediction model may decrease the frequency 
of invasive staging procedures—thereby decreasing risks, and 
potentially, costs—while taking into account an institution’s 
and/or provider’s risk tolerance for failing to diagnose pN2 
disease. An even more provocative application of prediction 
models in lung cancer staging is to tailor the probability cutoff 
to the patient’s risk tolerance, thereby promoting shared deci-
sion making between provider and patient.
Despite the potential benefits of a prediction model 
for lung cancer staging, there remains uncertainty about its 
impact on outcomes. Better staging can lead to better out-
comes only if (1) the information garnered from more accu-
rate staging leads to a change in management, which in turn 
leads to better outcomes; and (2) the change in management 
occurs frequently enough to realize these expected benefits. 
Meta-analyses of randomized trials show that both induction 
chemotherapy followed by resection24 and resection followed 
by adjuvant chemotherapy25 are superior to resection alone. 
However, in terms of long-term survival, there is no evidence 
that induction therapy is superior to adjuvant therapy.26–28 
Evidence shows that patients tolerate chemotherapy better 
preoperatively than postoperatively,27 supporting the conven-
tional wisdom. The benefits of a prediction model may be best 
quantified in terms of health-related quality of life.
The goal of developing future models is to improve their 
performance well beyond what is reported by us and other 
investigators.19,21 A novel approach is to identify molecular 
characteristics associated with nodal metastases and to incor-
porate molecular variables into existing prediction models. 
The presence of gene mutations is currently used to guide 
treatment decisions in lung cancer care29,30 but not diagnostic 
decisions. We attempted to identify an association between 
TABLE 5.  Exploratory Analysis of Alternative Invasive Staging Strategies
Measure
No Invasive 
Staging
High-Risk 
Tolerance
Empirically 
Derived Cutoff
Low-Risk 
Tolerance
Routine Invasive 
Staging
Cutoff for probability of pN2 disease (%) — 20 8.3 5.0 —
Model sensitivity for pN2 disease (%) — 27 77 97 —
Model specificity for pN2 disease (%) — 94 54 11 —
Proportion above cutoff (%) — 8 51 89 —
Percentage of pN2 disease detected before 
first therapy (%) (range)
0 10 (5–15) 40 (21–59) 48 (25–72) 50 (26–74)
Invasive procedures among patients without 
pN2 disease (%)
0 7 52 88 100
Empirical sensitivity of invasive staging 50% (95% confidence interval, 25%–74%).
pN2, pathologic N2.
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pN2 disease and mutations among patients who had under-
gone mutational analysis of EGFR or KRAS as part of their 
routine care. Unfortunately, we were unable to demonstrate 
any relationship with pN2 disease. Given the burgeoning 
number of mutations discovered among patients with squa-
mous cell lung cancer and AC of the lung,31,32 opportunities 
remain to enhance model performance through incorporation 
of molecular and genetic information.
Our study has several limitations not previously dis-
cussed. A key limitation is the nonuniform approach to intra-
operative nodal evaluation across surgeons. Accordingly, the 
true prevalence of pN2 disease is unknown and has potentially 
been underestimated. However, the extent to which nodal stag-
ing was misclassified is likely small because significant survival 
differences were observed across pathologic nodal stages. Had 
significant misclassification occurred, these survival differences 
would have been blunted or nonexistent. Nonetheless, a small 
degree of misclassification of pN2 status may have affected the 
predictive ability of the model. Another important limitation is 
the generalizability of our results to other centers. We attempted 
to define the cohort in a manner that would resemble the types 
of patients (straightforward, radiographically diagnosed early-
stage lung cancer) that most providers in the community 
would likely encounter. Nevertheless, the composition of our 
cohort may still not be representative of patients elsewhere. 
Furthermore, exclusion of patients with radiographically staged 
T3 or T4 tumors may have also limited the generalizability of 
our results. Though practice guidelines recommend routine 
invasive mediastinal staging for these tumors,9 this practice may 
not be occurring in the community at large. In a national study 
of patients with T4 tumors, only 20% of patients undergoing 
an operation had previously received a mediastinoscopy.33 Even 
though patients with evidence of T3 or T4 tumors by CT and a 
negative mediastinum by PET constitute a small proportion of 
all patients with lung cancer, it may be worthwhile to include T3 
and T4 status as variables in future prediction models. Finally, 
it may also be valuable to broaden the outcome measure to 
include patients with pN1 or pN2 disease, particularly if pro-
viders are increasingly managing preoperatively detected pN1 
disease with induction therapy.
In summary, this study provides proof of principle that pre-
diction models for pN2 disease can be developed and validated 
among patients with lung cancer. A multi-institutional study is 
necessary to verify the external validity and generalizability of 
the model. As an interim step, an investigation is being designed 
to evaluate this model’s performance at an institution where 
mediastinoscopy is routinely performed for patients with central 
stage IA or IB or higher tumors. From a practical standpoint, 
use of such models may reduce unnecessary practice variation in 
selective invasive mediastinal staging. Furthermore, prediction 
models may reduce the frequency, and thus, the associated risks 
and costs of invasive staging procedures in lung cancer patients 
with a low probability of pN2 disease. The potential impact of 
prediction models on outcomes remains uncertain. It is to be 
hoped that lessons learned from this investigation will inform 
the development of future prediction models for pN2 disease.
TABLE A1.  Variation in Pretreatment Mediastinal Nodal 
Assessment by Invasive Staging Modality
Assessment
Mediastinoscopy 
(n = 88)
EBUS 
(n = 8)
TBNA 
(n = 1) p
Nodal stations sampled,  
median (range)
3 (0–4) 1 (0–3) 0 0.002
Nodes sampled,  
median (range)
5 (0–18) 1 (0–7) 0 <0.001
EBUS, endobronchial ultrasound; TBNA, transbronchial node aspiration.
TABLE A2.  Variation in Pretreatment Mediastinal Nodal Assessment by Surgeon
Assessment A (n = 21) B (n = 2) C (n = 9) D (n = 16) E (n = 2) F (n = 4) G (n = 2) H (n = 22) I (n = 19) p
Nodal stations sampled,  
median (range)
3 (0–4) 2 (2–2) 2 (1–4) 3 (2–4) 2.5 (2–3) 2.5 (0–4) 3 (2–4) 2 (0–3) 2 (0–4) 0.808
Nodes sampled,  
median (range)
7 (0–8) 2.5 (2–3) 3 (2–11) 6 (3–12) 2 (1–3) 3 (0–6) 9 (3–15) 4.5 (0–12) 4 (0–13) 0.008
TABLE A3.  Variation in Intraoperative Mediastinal Nodal Assessment by Approach to Resection
Assessment Open (n = 607) VATS (n = 276) Robotic (n = 55) p
Nodal stations sampled, median (range) 2 (1–5) 1 (1–4) 2 (1–4) <0.001
Nodes sampled, median (range)  4 (1–57)  2 (1–18)  5 (1–25) <0.001
VATS, video-assisted thoracoscopic surgery.
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